Chiasma

Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.

Chiasma advances U.S. commercial launch originally planned for fourth quarter Chiasma advances U.S. commercial launch originally planned for fourth quarter

Chiasma Announces U.S. Commercial Launch and Availability of MYCAPSSA®, the First and Only Oral Somatostatin Analog for Patients with Acromegaly

NEEDHAM, Mass., Aug.  17, 2020  (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to reduce the burden of chronic injections for people with rare diseases, today announced the online publication of its CHIASMA OPTIMAL (Octreotide capsules vs. Placebo Treatment In MultinationAL centers) Phase 3 clinical trial results in the prestigious endocrinologist-focused Journal of Clinical Endocrinology & Metabolism. The publication, entitled, “Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide therapy,” was lead authored by Susan Samson, M.D., Ph.D., FRCPC, FACE, who served as principal investigator of the CHIASMA OPTIMAL clinical trial.

Chiasma Announces Publication of Pivotal Data from the Phase 3 CHIASMA OPTIMAL Clinical Trial in the Journal of Clinical Endocrinology & Metabolism

Chiasma, Inc. (CHMA) CEO Raj Kannan on Q2 2020 Results - Earnings Call Transcript

MYCAPSSA® U.S. commercial launch planned for the fourth quarter

Chiasma Reports Second Quarter 2020 Results and Significant Progress on Launch Preparedness

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

Chiasma to Report Second Quarter 2020 Results on August 10

-- The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was maintained within normal limits at the end of the 48-week OLE period --    -- All MYCAPSSA responders (IGF-1 within normal limits) who enrolled into the OLE completed the 48-week period; 93% maintained their response at the end of this period --

Chiasma Announces 48-Week Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA® in Patients with Acromegaly

The company announced the pricing of a public offering of common stock.

Why Chiasma’s Shares Are Down Today

NEEDHAM, Mass., July  01, 2020  (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its proprietary Transient Permeability Enhancer (TPE®) delivery platform technology to reduce the burden of chronic injections for people with rare diseases, today announced the pricing of its previously announced underwritten public offering of 12,500,000 shares of its common stock and, to certain investors in lieu thereof, pre-funded warrants to purchase up to 5,000,000 shares of its common stock at an exercise price of $0.0001 per share. The public offering price of each share of common stock is $4.00 and the public offering price of each pre-funded warrant is $3.9999 per underlying share. In addition, Chiasma has granted the underwriters a 30-day option to purchase up to an additional 2,625,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. This offering is expected to close on or about July 6, 2020, subject to satisfaction of customary closing conditions.

Chiasma Announces Pricing of a Public Offering of $70 Million of Common Stock and Pre-Funded Warrants

Chiasma (CHMA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Is Chiasma (CHMA) Stock a Solid Choice Right Now?

NEEDHAM, Mass., June  30, 2020  (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its proprietary Transient Permeability Enhancer (TPE®) delivery platform technology to reduce the burden of chronic injections for people with rare diseases, today announced that it has commenced an underwritten public offering of its common stock, and, to certain investors in lieu thereof, pre-funded warrants to purchase shares of its common stock. In addition, Chiasma expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock plus the shares of common stock underlying the pre-funded warrants sold in connection with the offering. All of the securities to be sold in the offering are to be sold by Chiasma. This offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Chiasma Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Chiasma's Valuation Should Be Higher Than $5-6/Share Now That Mycapssa Is FDA Approved

Investors need to pay close attention to Chiasma (CHMA) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Chiasma (CHMA) Stock?

MYCAPSSA is indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with  octreotide or lanreotide

Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules, the First and Only Oral Somatostatin Analog

Chiasma, Inc. (CHMA) CEO Raj Kannan on Q1 2020 Results - Earnings Call Transcript

NEEDHAM, Mass., April  22, 2020  (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late stage biopharmaceutical company focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases, today announced the appointment of Anand Varadan as Executive Vice President, Chief Commercial Officer. Mr. Varadan will lead Chiasma’s commercial strategy and operations.

Chiasma Appoints Anand Varadan as Chief Commercial Officer and Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Chiasma, Inc. (CHMA) CEO Raj Kannan on Q4 2019 Results - Earnings Call Transcript

Chiasma Announces FDA Acceptance of MYCAPSSA® New Drug Application Resubmission

MYCAPSSA ® NDA resubmitted to FDA; PDUFA decision expected mid-2020

Chiasma Provides Corporate Update and Previews 2020 Milestones

NEEDHAM, Mass., Dec.  19, 2019  (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to market open on Monday, December 23, 2019.

Chiasma Added to NASDAQ Biotechnology Index

WALTHAM, Mass., Nov.  26, 2019  (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that Raj Kannan, Chief Executive Officer, and William Ludlam, M.D., Ph.D., Senior Vice President of Clinical Development and Medical Affairs, will participate in an analyst-led fireside chat at the Piper Jaffray 31st Annual Healthcare Conference, which is being held December 3rd to 5th  in New York, New York.  Management is scheduled to present on Tuesday, December 3rd at 8:30 a.m. ET.

Chiasma to Present at the Piper Jaffray 31st Annual Healthcare Conference

Chiasma, Inc. (CHMA) CEO Raj Kannan on Q3 2019 Results - Earnings Call Transcript

WALTHAM, Mass., Nov.  01, 2019  (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today recognizes November 1st as Acromegaly Awareness Day.   

Chiasma Supports Acromegaly Awareness Day

Chiasma (CHMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Chiasma (CHMA) a New Buy Stock

When we first visited all-or-nothing drug delivery concern and busted IPO Chiasma last October, it had just completed enrollment of two Phase 3 trials for the treatment of acromegaly.

Chiasma: The Investment Thesis Improves

WALTHAM, Mass., Sept.  05, 2019  (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, will host a Key Opinion Leader (KOL) breakfast on maintenance therapy of adult patients with acromegaly on Thursday, September 12, 2019 in New York City.

News for Chiasma Stock (CHMA)